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Background: The role of biomarkers for prognostication and diagnosis of pulmonary embolism (PE) is increasing. It
has been reported that pregnancy-associated plasma protein-A (PAPP-A) can be used as a proatherosclerotic
marker. The present study was aimed to evaluate whether PAPP-A levels are helpful in the differential diagnosis of
patients presenting with suspected PE.
Methods: 53 consecutive patients evaluated for suspected PE were prospectively enrolled in the study. Serum
PAPP-A levels were measured in the blood samples which were taken at admission. Multi-slice computed
tomographic angiography was used to verify the diagnosis of PE.
Results: PE was detected in 24 out of the 53 patients, while it was excluded in 29 patients by thorax multi-detector
computerized tomography scan. No significant difference was detected in mean serum PAPP-A level between
groups (5.72 ± 0.31 mg/L vs. 5.67 ± 0.06 mg/L, respectively).
Conclusions: Serum PAPP-A level has no role in the evaluation for PE.
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Pulmonary embolism (PE) is an important clinical entity
with high mortality and morbidity. Particularly, mortality
is determined by hemodynamic status and underlying
disease. The role of biomarkers for the prognostication
and diagnosis of PE is increasing [1,2].
The pregnancy-associated plasma protein-A (PAPP-A)
is a matrix metalloproteinase which is an activator of
insulin-like growth factor-1. The PAPP-A with elevating
serum levels by the progression of pregnancy is mainly
used as a part of screening tests for Down syndrome
[3]. Moreover, it has been reported that its serum level
is increased during plaque rupture process in acute
coronary syndromes, suggesting that it can be used as
a proatherosclerotic marker [4]. The present study was
aimed to evaluate whether PAPP-A levels are helpful* Correspondence: serdar.berk@yahoo.com
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reproduction in any medium, provided the orin the differential diagnosis of patients presented with
suspected PE.Methods
Overall, 53 consecutive patients presenting to our hospital
in the last six months with suspected PE were prospectively
enrolled to the study. The study was approved by Local
Ethic Committee of the University. All patients gave
written informed consent. Demographic characteristics
and clinical findings were recorded. The routine laboratory
(e.g. complete blood count, liver and kidney function tests,
D-dimer and Troponin I measurements, arterial blood gas
analysis and ECG) and radiological evaluations (e.g. chest
X-ray and thoracic CT scan) were performed to establish or
exclude the diagnosis of PE.
Besides, routine laboratory evaluations were performed
to establish or exclude the diagnosis of PE, and multi-slice
thorax CT angiography was performed for definitive diag-
nosis. All CT evaluations were performed by using 16-
slice MDCT scanner (Brilliance iCT, Philips Healthcare,
Cleveland OH, USA) and automatic intravenous contrast. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Sixty eight-year-old female patient with
pulmonary emboli.
Table 1 Comparison of clinical and radiological findings






n (%) n (%)
Sex (men) 13 (54) 14(48) 0.669
Symptoms
Shortness of breath 18 (75) 25 (86) 0.299
Chest pain 14 (58) 25 (86) 0.098
Palpitation 12 (50) 10 (34) 0.254
Cough 11 (45) 21 (72) 0.049*
Leg swelling 8 (33) 9 (31) 0.858
Hemoptysis 5 (20) 3 (10) 0.288
Physical examination findings
Crackles 14 (58) 22 (76) 0.174
Ronchus 4 (17) 7 (24) 0.504
Cyanosis 6 (25) 13 (44) 0.134
Tachycardia 5 (20) 6 (20) 0.990
Tachypnea 4 (17) 10 (34) 0.143
Radiological findings
Infiltration 14 (58) 22 (76) 0.174
Cardiomegaly 16 (66) 14 (48) 0.179
Linear atelectasis 7 (29) 9 (31) 0.883
Pleural effusion 5 (20) 9 (31) 0.402
Elevation of the Diaphragm 3 (12) 4 (14) 0.890
*p < 0.05 significant difference.
PE: Pulmonary embolism.
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Injection Systems (Stellant, Medrad, Indianola, USA).
Scanning was performed while patients were in a supine
position with both arms being next to head, and lasted ap-
proximately 10 seconds. The following acquisition param-
eters were used: 120 kV; 200 mAs; collimation 16×0.75;
pitch value 0.9; and gantry rotation time 0.5. A scanogram
was obtained that primarily involves thoracic outlet and
diaphragm. The area from diaphragm to aortic arc was
identified as region of interest. A tracker was placed at
pulmonary trunk to automatically trigger acquisition
when contrast material reached to 120 HU within pulmon-
ary artery. First, the area between aortic arc and diaphragm
was scanned with a slice thickness of 2 mm. Then, the area
between aortic arc and thoracic outlet was scanned with a
slice thickness of 0.5 mm. Non-ionic iodine (350 mg/mL)
was used as contrast material. Axial, coronal and sagittal
planes were assessed by volume rendering Maximum
Intensity Projection (MIP) and Multiplanar Reformation
(MPR) techniques. In these assessments, standard medi-
astinal (350/40) and pulmonary (-700/1000) windows
were used. The images of multi-slice CT angiography
were assessed for presence of embolism in main, lobar,
segmental and subsegmental arteries and for sufficiency
of vascular contrast enhancement.
Blood samples (5 ml) were drawn into plain tubes
to measure PAPP-A levels at presentation. Than samples
were centrifuged and sera obtained were stored at -80°C
until assays. Before analysis, sera awaited at room
temperature. PAPP-A levels were measured by EIA method
using ultrasensitive ELISA kit (ELIZEN PAPP-A; Zentech,
Angleur, Belgium). Pregnant women, and those with
prerenal azotemia, renal failure, liver disease, diabetes,
known hypertension and heart diseases were excluded.
Statistical analysis
The descriptive statistics (mean, standard deviation,
frequency) as well as Chi-square and Student’s t tests
were used in the data analysis.
Results
On the thorax multi-slice CT angiography, PE was detected
in 24 patients (PE+) (Figure 1), while it was excluded in 29
(PE-) of 53 patients. Out of the 29 patients without
PE, 20were affected with pneumonia, 5 with COPD ex-
acerbation, one with Dressler syndrome and onewith empy-
ema, while restrictive pulmonary disorders causing acute
respiratory stress was detected in two patients. Mean age
was 62 ± 17 years in 24 patients with PE, and 63 ± 15 years
in 29 patients without PE. 48% of the patients with PE were
women, whereas 52% of those without PE were women.
The mean age and sex distribution were similar in both
groups (p > 0.05). While cough was more frequent in pa-
tients without PE, other clinical, radiological and laboratoryfinding were found to be similar in both groups (Tables 1
and 2). The distribution of serum PAPP-A values was
similar in both groups (Figure 2). No significant differ-
ence was found in mean serum PAPP-A levels between
groups (5.72 ± 0.31 mg/L vs. 5.67 ± 0.06 mg/L, respectively;
p = 0.399).
Table 2 Comparison of laboratory features of the
study groups
Parameters PE(+) PE(-) p
Mean ± SD Mean ± SD
Age (year) 62 ± 17 63 ± 15 0.720
BMI (kg/m2) 28 ± 4 27 ± 3 0.308
Hearth rate (breaths/min) 88 ± 15 92 ± 20 0.511
SBP (mmHg) 121 ± 30 126 ± 29 0.515
DBP (mmHg) 73 ± 17 75 ± 12 0.504
Respiratory rate (breaths/min) 23 ± 3 26 ± 4 0.021*
Body temperature 36.7 ± 0.6 36.5 ± 0.8 0.546
pH 7.43 ± 0.06 7.42 ± 0.07 0.675
PaO2(mmHg) 55.6 ± 15.2 61.8 ± 18.1 0.286
PaCO2(mmHg) 37.3 ± 6.3 36.5 ± 7.6 0.680
SaO2 (%) 87.0 ± 7.5 89.8 ± 6.6 0.222
CRP (mg/L) 57 ± 62 81 ± 92 0.293
WBC (x103/μL) 11.6 ± 5.6 15.3 ± 14.2 0.239
Hb (g/dl) 13.3 ± 2.6 13.6 ± 2.3 0.678
Ht (%) 40.8 ± 8.3 40.3 ± 6.6 0.396
PLT (x103) 266 ± 105 260 ± 107 0.865
D-Dimer (ng/ml) 2938 ± 3471 1968 ± 3106 0.313
PAPP-A (mIU/ml) 5.72 ± 0.31 5.67 ± 0.06 0.399
BMI: Body mass index, CRP: C-reactive protein, DBP: Diastolic blood pressure,
Hb: Hemoglobin, Ht: Hematocrit, PLT: Platelet, PAPP-A: Pregnancy-associated
plasma protein-A, SBP: Systolic blood pressure, SD: Standard deviation, WBC:
White blood cells.
*p < 0.05 significant difference.
Figure 2 Distribution of serum PAPP-A values of two groups.
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Pulmonary embolism is characterized by the formation
of a blood clot in a vein, which will begin to travel
through the circulatory system and will become lodged
within the pulmonary arterial system. Clinics, radiology,
and laboratory findings in patients with PE are associated
with the degree of occlusion of arteries, and the cardiopul-
monary reserve of the patient. Dyspnoea, pleuritic chest
pain, cough, haemoptysis, mild fever, tachypnea, tachycar-
dia, and crackles are the most common symptoms and
signs in patients with PE. Atelectasis, pleural effusion,
pulmonary infiltrates, and mild elevation of a hemi dia-
phragm may be seen on chest X-ray. Elevated D-dimer,
leukocytosis, hypoxemia may be seen [5]. These findings
are nonspecific and can be seen in pneumonia, pleurisy,
acute exacerbation of chronic lung disease, acute coronary
syndromes, acute congestive heart failure or pulmonary
oedema, pneumothorax, and dissecting or rupturing aortic
aneurysm [6]. Richman et al. reported 81% pneumonia,
7% aortic aneurysm or dissection, and 7% mass suggesting
undiagnosed malignancy were found in patients whom PE
were ruled out by chest computed tomography angiog-
raphy, in emergency departments patients with symptoms
suspicious for PE [7]. Main symptoms and features were
shortness of breath, chest pain, crackles, infiltration, and
cardiomegaly in patients with or without PE (detected or
ruled out by multi-slice CT angiography), in our study.
Routine blood tests and arterial blood gases (ABG) results
were not different between groups. Pneumonia (70%), and
acute exacerbation of COPD (5%) were the main diagnosis
in the PE negative group. As revealed in previous studies,
symptoms and signs, physical examination, conventional
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may not reveal or rule out PE in patients with suspected
PE, which is supported by our study.
The pregnancy-associated plasma protein-A (PAPP-A)
is a matrix metalloproteinase which is primarily synthesized
and released to circulation by placental trophoblasts during
pregnancy. It is used for screening of Down syndrome in
pregnancy [3]. In a study on vascular smooth muscle cells
obtained from human coronary arteries, Bayes-Genis et al.
demonstrated that vascular smooth muscles cells are able
to synthesize and release PAPP-A. Authors also reported
that PAPP-A cause plaque progression and destabilization
by contributing inflammatory cytokine release from mac-
rophages and LDL-cholesterol accumulation [4]. In the
light of these data, several studies have been performed
suggesting that PAPP-A, an inflammatory marker like
CRP, may be used in both diagnosis and prognostication
of acute coronary syndromes [8-12]. It has been thought
that PAPP-A might be a marker of unstable plaque rupture
in patients with sudden cardiac death [9]. The elevation
of PAPP-A may be an independent predictor of ische-
mic events [10]. There is a weak correlation between
PAPP-A and CK-MB; thus, the elevation of PAPP-A
may not be related to necrosis. In acute coronary syn-
dromes, it has been proposed that the disruption of
plaque stability by proteolytic enzymes released due to
local inflammation is accounted from the rupture of
atherosclerotic plaques within vessel in acute coronary
syndromes [11]. The inflammation is not only local but also
systemic [12]. Liuzzo et al. reported that CRP, the prototype
marker of inflammation, was elevated in coronary diseases
[13]. On the other hand, CRP may increase in many
diseases, especially in pneumonia, as it is a non-specific
inflammatory marker.
There are some studies investigating whether serum
PAPP-A levels are increased in conditions other than
pregnancy and atherosclerotic events. Bulut et al. reported
that PAPP-A, as an inflammatory marker, was increased
in patients with lung cancer [14]. Again, in another
study it has been shown that PAPP-A release might play
an important role in the development and progression
of lung cancer [15].
In another study, it has been reported that serum
PAPP-A level was significantly higher in asthmatic patients
when compared with healthy controls and there was a
correlation between severity of asthma and serum
PAPP-A level [16]. Fialova et al. reported that serum
PAPP-A levels were increased in chronic renal diseases
in relation to oxidative stress and inflammation [17].
In a study investigating serum PAPP-A levels in 1,448
patients with different disorders but not coronary artery
disease, no significant elevation was detected in serum
PAPP-A levels across any diseases subgroup. In addition,
no correlation was detected between serum PAPP-A leveland other inflammatory markers such as NT-proBNP,
creatinine or CRP. The PAPP-A might potentially be a
specific marker for heart diseases but it seems to have
lower specificity in patients without coronary heart
disease [18]. However, to our knowledge, there is no
study evaluating the relation between PE and PAPP-A
in English literature.
In our study, PE was confirmed in 24 out of the 53
patients with suspected PE, while it was excluded in 29
patients. Of the patients in whom PE was excluded,
about 70% had pneumonia. No significant difference was
found in serum CRP and PAPP-A levels between the
two groups. This can be explained by the presence of
inflammation in both conditions. Although there are no
sufficient data in this context, we think that our results
are in agreement with the literature in general. Lack of
healthy control group may be seen as a limitation. How-
ever, it would not be useful in the differential diagnosis
of PE, even if serum PAPP-A levels are significantly
higher than healthy controls.Conclusions
In conclusion, serum PAPP-A level has no significant
role either to establish the diagnosis or in differential
diagnosis in patients with suspected PE.
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